4CPS-101 Intravenous immunoglobulins use for children’s neurological and neurodevelopmental disorders

Abstract

Conclusion Given the existing low degree of evidence, this study shows that there are no clear advantages of this medication in patients with cystic fibrosis and neuromuscular problems. Consequently, and given the high cost that palivizumab use implies, it would be necessary to establish protocols that define use condition and identification of patients that may benefit better from the treatment.